Trial reportTransfusion medicine (Oxford, England)2026
Extracorporeal photopheresis-New insights into an old procedure.
Trial report in Transfusion medicine (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracorporeal photopheresis-New insights into an old procedure.Transfusion medicine (Oxford, England) · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundExtracorporeal photopheresis (ECP) is a safe immunomodulatory strategy that induces cell-type selective apoptosis through photodynamic processes. Despite decades of use, the mechanisms underlying ECP remain largely unexplored, particularly in studies examining specific immune cell subsets in ex vivo setups.
aimsThis proof-of-concept pilot study presents data on apoptosis and proliferation of T-lymphocytes following ex vivo ECP application to leukocyte concentrates (LC) and peripheral blood (PB) samples from healthy donors.
methodsLC and PB were diluted to a haematocrit of 2% and treated with 8-methoxypsoralen, followed by ECP (ECP+) or no ECP (ECP-) in a discontinued system. Apoptosis of mononuclear cells was assessed 48 h post-ECP using annexin V and 7 Aminoactinomycin D (7-AAD) staining with flow-cytometric quantification. The proliferative capacity of non-apoptotic T-lymphocytes was measured after 72 h of post-ECP stimulation with anti-CD3/CD28 cross-linking, using Violet Proliferation Dye 450.
resultsECP exposure significantly reduced the median T-cell receptor-induced proliferation of viable T-lymphocytes from both LC (4.6%, p = 0.02) and PB (4.2%, p = 0.03). However, 7-AAD staining 48 h post-ECP showed no significant differences in the proportions of apoptotic cells in this experimental model.
conclusionEx vivo ECP treatment inhibited T-lymphocyte proliferation in both LC and PB from healthy individuals, suggesting this as a key mode of action. Our findings highlight ECP's potential applications, including its implications for modern immune therapies' adverse effects. Further analyses of functional characteristics of remaining vital cells are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.